Show document

A+ | A- | | SLO | ENG

Title: MHC class II molecules and tumour immunotherapy Authors: ID Oven, Irena (Author) Files: PDF - Presentation file, download (168,54 KB) MD5: 11D234AABCED69775E2F26461224734D   Language: English Typology: 1.02 - Review Article Organization: OI - Institute of Oncology Abstract: Tumour immunontherapy attempts to use the specificity and capability of the immune system to kill malignant cells with a minimum damage to normal tissue. Increasing knowledge of the identity of tumour antigens should help us design more effective therapeutic vaccines. Increasing evidence has demonstrated that MHC class II molecules and CD4+T cells play important roles in generating and maintaining antitumour immune responses in animal models. These data suggest that be necessary to involve both CD+ and CD+T cells for more effective antitumour therapy. Novel strategies have been developed for enhancing T cell responses against cancer by prolonging antigen prersentation of denritic cells to T cells, by the inclusion of MHC class II-restricted tumour antigens and by genetically modifying tumour cells to present antigen to T lymphocytes directly. Vaccines against cancers aim to induce tumour-specific effector T cells that can reduce tumour mass and induce development of tumour-specific T cell memory, that can control tumour relapse. Publication status: Published Publication version: Version of Record Publication date: 01.01.2005 Publisher: Association of Radiology and Oncology Year of publishing: 2005 Number of pages: str. 261-268 Numbering: Letn. 39, št. 4 Source: Ljubljana PID: 20.500.12556/DiRROS-18164  UDC: 616-006 ISSN on article: 1318-2099 COBISS.SI-ID: 1837704  Copyright: by Authors Publication date in DiRROS: 14.02.2024 Views: 163 Downloads: 33 Metadata:     Cite this work Plain text BibTeX EndNote XML EndNote/Refer RIS ABNT ACM Ref AMA APA Chicago 17th Author-Date Harvard IEEE ISO 690 MLA Vancouver : Copy citation

Share: Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:	Radiology and oncology
Shortened title:	Radiol. oncol.
Publisher:	Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:	1318-2099
COBISS.SI-ID:	32649472

Secondary language

Language:	Slovenian
Title:	[Pomen molekul MHC pri imunoterapiji tumorjev]
Abstract:	Izhodišča. Imunoterapija tumorjev izrablja sposobnost imunskega sistema, da se specifično ubija tumorske celice, pri tem pa minimalno poškoduje normalno tkivo. Vedno večje poznavanje tumorskih celic, pri tem pa minimalno poškoduje normalno tkivo. Vedno večje poznavanje tumorskih antigenov prispeva k načrtovanju bolj učinkovitih terapevtskih cepiv. Študije narejene na živalskih modelih so pokazale, da so poleg molekul MHC I in celic CD8+ T pri nastanku in vzdrževanju imunskega odziva proti tumorjem pomembne tudi molekuleMHC II in celice CD4+ T. Rezultati nakazujejo, da bo za učinkovito protitumorsko cepivo potrebno aktivirati tako celice CD4+ kot tudi CD8+ T. V zadnjem času so se razvile nove strategije za okrepitev T celičnega odgovora proti raku, ki izrabljajo sposobnost dendritiènih celic, da delujejo kot antigeni. Z vključevanjem tumorskih antigenov specifičnih za molekule MHC II in z genetičnim spreminjanem tumorskih celic, da delujejo kot antigeni (antigen-predstavitvene celice), lahko podaljšamo predstavljanje antigenov celicam T preko dendritičnih celic. Zaključki. Z združitvijo različnih pristopov bi lahko naredili učinkovito protitumorsko cepivo, ki bi vzpodbudilo delovanje za tumor specifičnih celic T, te pa bi ubile tumorske celice. S tem bi zmanjšale obseg tumorja, obenem pa bi vzpodbudile tudi nastanek za tumor specifičnega celičnega spomina T, ki bi omejil ali preprečil ponovni nastanek tumorja.
Keywords:	klinična medicina, rak, onkologija, tumorji, imunoterapija

Back